Novartis (NVSN) AI Stock Analysis

Novartis

(BMV:NVSN)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Growth portfolio momentumStrong growth across multiple priority brands shows that Novartis has several commercially advancing products rather than relying on one medicine. Broad momentum across oncology, immunology, neuroscience and cardiovascular therapies supports durable revenue replacement as older products face erosion.

Negative Factors

Higher financial leverageThe sharp increase in debt relative to equity reduces balance-sheet flexibility and makes the company more sensitive to earnings volatility and financing costs. Higher leverage can constrain capital allocation if pipeline spending or commercial performance weakens.

Novartis (NVSN) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 303.67B
Dividend Yield: 2.97%
Average Volume (3M): 80
Price to Earnings (P/E): 31.2
Beta (1Y): 0.30
Revenue Growth: -8.64%
EPS Growth: -35.71%
Country: Mexico
Employees: 75,267
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - General

Novartis Business Overview & Revenue Model

Company Description

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscie...

Novartis Earnings Call Summary

Earnings Call Date:Oct 26, 2026(Q3-2026)|% Change Since:4.06%|Next Earnings Date:Feb 02, 2027

Earnings Call SentimentPositive

The call was predominantly positive, supported by 4% quarterly sales growth, 10% core operating income growth, 29% priority-brand growth, strong performance from key brands, positive remibrutinib data, multiple regulatory milestones and an upgrade to full-year core operating income guidance. However, reported earnings and nine-month results were weaker, while delgociptacine and pelacarsen had unsuccessful Phase 3 outcomes, Rhapsido autoimmune studies remain on hold, and generic and biosimilar pressures are expected to affect future performance. Highlights significantly outweighed the explicitly stated challenges.

Positive Updates

Q3 Sales, Core Operating Income and Margin Expansion

Third-quarter net sales grew 4% in constant currencies to $14.5 billion, core operating income grew 10% to $6 billion, and core operating margin increased by 2 percentage points year over year to 41.6%, mainly driven by gross margin improvements, growth drivers and continued SG&A productivity.

Negative Updates

Reported Operating Income and Net Income Declined Sharply

Reported Q3 operating income was $1.8 billion, down 61%, and net income was $1.2 billion, down 71%. The changes were mainly attributed to higher R&D expenses, the $1.9 billion partial impairment of delgociptacine, lower operating income and higher interest income as stated on the call.

Company Guidance

For full year 2026, Novartis expects core operating income to be in line to growing low single digit, net sales to grow at low single digit, core net financial results to be an expense of $1.7 billion, and the core tax rate to be around 16.5%; for H2, net sales are expected to grow mid to high single digit and core operating income high single to low double digit. The company reaffirmed 5% to 6% constant currency sales guidance for 25 to 30 and its mid single digit constant currency long term growth outlook, expects to reach 40% margin by 2029, raised Rhapsido peak sales guidance to over $4 billion and expects a $10 billion-plus medicine for remibrutinib, while maintaining $10 billion peak sales guidance for Kisqali, $4 billion plus for Leqvio, and $3 billion for Fabhalta; if exchange rates remain at late October levels, it expects a positive 1 percentage point impact on full year net sales and a positive 1 percentage point impact on full year core operating income.

Novartis Risk Analysis

Novartis disclosed 26 risk factors in its most recent earnings report. Novartis reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks

1.Artificial IntelligenceQ4, 2025

2.Social impact and sustainability mattersQ4, 2025

3.Competition and commercial prioritiesQ4, 2025

Novartis Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

MX:NVSN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LLY	81Outperform	$1.33T	45.89	83.65%	0.47%	45.51%	50.48%
PFE	74Outperform	$173.95B	40.33	4.89%	5.64%	-0.21%	-59.71%
SNY	71Outperform	$106.82B	24.39	5.52%	5.46%	23.68%	-30.90%
JNJ	70Outperform	$657.68B	41.42	19.55%	1.93%	7.81%	-35.95%
MRK	63Neutral	$368.89B	152.57	5.10%	2.27%	5.16%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

MX:NVSN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MX:NVSN	Novartis AG	2911.00	605.95	26.29%
LLY	Eli Lilly And Company	1417.54	526.63	59.11%
JNJ	Johnson & Johnson	273.20	91.04	49.98%
MRK	Merck & Company	149.52	69.38	86.58%
PFE	Pfizer Inc	30.52	7.48	32.45%
SNY	Sanofi SA	44.34	-3.79	-7.87%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Novartis AI Stock Analysis